ProfileGDS4814 / ILMN_1789593
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 72% 71% 70% 72% 73% 71% 72% 70% 71% 71% 74% 73% 72% 71% 71% 74% 72% 71% 75% 72% 67% 71% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)80.610372
GSM780708Untreated after 4 days (C2_1)75.727771
GSM780709Untreated after 4 days (C3_1)73.172970
GSM780719Untreated after 4 days (C1_2)79.45572
GSM780720Untreated after 4 days (C2_2)88.842173
GSM780721Untreated after 4 days (C3_2)79.15271
GSM780710Trastuzumab treated after 4 days (T1_1)80.815872
GSM780711Trastuzumab treated after 4 days (T2_1)72.680270
GSM780712Trastuzumab treated after 4 days (T3_1)75.572971
GSM780722Trastuzumab treated after 4 days (T1_2)78.833471
GSM780723Trastuzumab treated after 4 days (T2_2)91.498374
GSM780724Trastuzumab treated after 4 days (T3_2)88.437373
GSM780713Pertuzumab treated after 4 days (P1_1)83.258372
GSM780714Pertuzumab treated after 4 days (P2_1)77.619971
GSM780715Pertuzumab treated after 4 days (P3_1)78.363271
GSM780725Pertuzumab treated after 4 days (P1_2)93.79174
GSM780726Pertuzumab treated after 4 days (P2_2)80.256772
GSM780727Pertuzumab treated after 4 days (P3_2)76.17571
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)97.99375
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)82.651172
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)64.167367
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)76.530471
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)82.326172